Renoprotective Effect of Calcium Channel Blockers in Combination with an Angiotensin Receptor Blocker in Elderly Patients with Hypertension. A Randomized Crossover Trial Between Benidipine and Amlodipine

REFERENCES

• Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334:13–18.
   PubMed Web of Science ®Google Scholar
• Executive summary. United States Renal Data System, 1999 Annual Data Report. Am J Kidney Dis 1999;34(2 suppl 1): S9–S19.
   PubMedGoogle Scholar
• Locatelli F, Del Vecchio L, D'Amico M, Andrulli S. Is it the agent or the blood pressure level that matters for renal protection in chronic nephropathies? J Am Soc Nephrol 2002; 13(suppl 3):S196–201.
   PubMedGoogle Scholar
• Kundhal K, Lok CE. Clinical epidemiology of cardiovascular disease in chronic kidney disease. Nephron Clin Pract 2005; 101:c47–52.
   PubMed Web of Science ®Google Scholar
• Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA 1992;268:3085–3091.
   PubMed Web of Science ®Google Scholar
• Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754–762.
   PubMed Web of Science ®Google Scholar
• Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277:739–745.
   PubMed Web of Science ®Google Scholar
• Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, Coope J, Ekbom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard RH. Risks of untreated and treated isolated systolic hypertension in the elderly: Meta-analysis of outcome trials. Lancet 2000;355:865–872.
   PubMed Web of Science ®Google Scholar
• Viberti G, Wheeldon NM; Microalbuminuria Reduction with Valsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 2002;106:672–678.
   PubMed Web of Science ®Google Scholar
• Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS; AIPRD Study Group. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med 2003;139:244–252.
   PubMed Web of Science ®Google Scholar
• MacGregor MS, Deighan CJ, Rodger RS, Boulton-Jones JM. A prospective open-label randomised trial of quinapril and/or amlodipine in progressive non-diabetic renal failure. Nephron Clin Pract 2005;101:c139–c149.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003;289:2560–2572.
   PubMed Web of Science ®Google Scholar
• Japanese Society of Hypertension. Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006;29 (suppl):S1–105.
   PubMedGoogle Scholar
• Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens 2007;25:1105–1187.
   PubMed Web of Science ®Google Scholar
• Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527–1535.
   PubMed Web of Science ®Google Scholar
• Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: An update including the 2003–2004 secondary prevention trials. Hypertens Res 2005; 28:385–407.
   PubMed Web of Science ®Google Scholar
• UKPDS 38. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998; 317:703–713.
   PubMed Web of Science ®Google Scholar
• Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 2005;366:2026–2033.
   PubMed Web of Science ®Google Scholar
• Hasebe N, Kikuchi K; NICE Combi Study Group. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: The NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens 2005;23:445–453.
   PubMed Web of Science ®Google Scholar
• Saito F, Fujita H, Takahashi A, Tchiyama I, Harasawa S, Oiwa K, Takahashi N, Otsuka Y, Uchiyama T, Kanmatsuse K, Kushiro T. Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria. Hypertens Res 2007; 30:39–47.
   PubMed Web of Science ®Google Scholar
• Hansen PB, Jensen BL, Andreasen D, Skott O. Differential expression of T- and L-type voltage-dependent calcium channels in renal resistance vessels. Circ Res 2001;89:630–638.
   PubMed Web of Science ®Google Scholar
• Furukawa T, Nukada T, Miura R, Ooga K, Honda M, Watanabe S, Koganesawa S, Isshiki T. Differential blocking action of dihydropyridine Ca2+ antagonists on a T-type Ca2+ channel (alpha1G) expressed in Xenopus oocytes. J Cardiovasc Pharmacol 2005;45:241–246.
   PubMed Web of Science ®Google Scholar
• Morikawa T, Okumura M, Konishi Y, Okada N, Imanishi M. Effects of benidipine on glomerular hemodynamics and proteinuria in patients with nondiabetic nephropathy. Hypertens Res 2002;25:571–576.
   PubMed Web of Science ®Google Scholar
• Uzu T, Nishimura M, Fujii T, Sakaguchi M, Kanasaki M, Isshiki K, Araki S, Sugiomoto T, Kashiwagi A, Kimura G. Benidipine attenuates glomerular hypertension and reduces albuminuria in patients with metabolic syndrome. Hypertens Res 2007;30:161–165.
   PubMed Web of Science ®Google Scholar
• Yao K, Sato H, Ina Y, Suzuki K, Ohno T, Shirakura S. Renoprotective effects of benidipine in combination with angiotensin II type 1 receptor blocker in hypertensive Dahl rats. Hypertens Res 2003;26:635–641.
   PubMed Web of Science ®Google Scholar
• Long DA, Mu W, Price KL, Johnson RJ. Blood vessels and the aging kidney. Nephron Exp Nephrol 2005;101:e95–e99.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hall JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421–426.
   PubMed Web of Science ®Google Scholar
• Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE study. Ann Intern Med 2003;139:901–906.
   PubMed Web of Science ®Google Scholar
• Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, Appleyard M, Jensen JS. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004;110:32–35.
   PubMed Web of Science ®Google Scholar
• Dohi Y, Kojima M, Sato K. Benidipine improves endothelial function in renal resistance arteries of hypertensive rats. Hypertension 1996;28:58–63.
   PubMed Web of Science ®Google Scholar
• Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007;72:1543–1549.
   PubMed Web of Science ®Google Scholar
• Fleming JT, Parekh N, Steinhausen M. Calcium antagonists preferentially dilate preglomerular vessels of hydronephrotic kidney. Am J Physiol 1987;253:F1157–1163.
   PubMed Web of Science ®Google Scholar
• Carmines PK, Navar LG: Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to ANG II. Am J Physiol 1989;256:F1015–1020.
   PubMed Web of Science ®Google Scholar
• Sugano N, Wakino S, Kanda T, Homma K, Yoshioka K, Hasegawa K, Hara Y, Suetsugu Y, Yoshizawa T, Hara Y, Utsunomiya Y, Tokudome G, Hosoya T, Saruta T, Hayashi K. T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy. Kidney Int 2008;73:826–834.
   PubMed Web of Science ®Google Scholar
• Ohishi M, Takagi T, Ito N, Terai M, Tatara Y, Hayashi N, Shiota A, Katsuya T, Rakugi H, Ogihara T. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: An amlodipine-to-benidipine changeover (ABC) study. Hypertens Res 2007;30:797–806.
   PubMed Web of Science ®Google Scholar
• Asayama K, Ohkubo T, Kikuya M, Obara T, Metoki H, Inoue R, Hara A, Hirose T, Hoshi H, Hashimoto J, Totsune K, Satoh H, Imai Y. Prediction of stroke by home “morning” versus “evening” blood pressure values: The Ohasama study. Hypertension 2006;48:737–743.
   PubMed Web of Science ®Google Scholar
• Kario K, Ishikawa J, Pickering TG, Hoshide S, Eguchi K, Morinari M, Hoshide Y, Kuroda T, Shimada K. Morning hypertension: the strongest independent risk factor for stroke in elderly hypertensive patients. Hypertens Res 2006; 29:581–587.
   PubMed Web of Science ®Google Scholar
• Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Dahlof B, Devereux RB, Kjeldsen SE, Oikarinen L, Okin PM; LIFE Study Investigators. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 2006;24:775–781.
   PubMed Web of Science ®Google Scholar
• Pontremoli R, Leoncini G, Viazzi F, Ratto E, Vaccaro V, Falqui V, Parodi A, Conti N, Tomolillo C, Deferrari G. Evaluation of subclinical organ damage for risk assessment and treatment in the hypertensive patient: Role of microalbuminuria. J Am Soc Nephrol 2006;17(4 suppl 2):S112–114.
   PubMed Web of Science ®Google Scholar
• Herrera-Pombo JL, Aguilar-Diosdado M, Hawkins F, Campos MM, Moreno A, Garcia-Hernandez A, Castro E, Garcia-Doncel LG, Serraclara A, Sanchez-Malo C, Escobar-Jimenez F. Is increasing urinary albumin a better marker for microvascular than for macrovascular complication of type 2 diabetes mellitus? Nephron Clin Pract 2005;10:c116–c121.
   Google Scholar
• Fukuda M, Munemura M, Usami T, Nakao N, Takeuchi O, Kamiya Y, Yoshida A, Kimura G. Nocturnal blood pressure is elevated with natriuresis and proteinuria as renal function deteriorates in nephropathy. Kidney Int 2004;65:621–625.
   PubMed Web of Science ®Google Scholar
• Fukuda M, Kimura G. Pathophysiology of antihypertensive therapy with diuretics. Hypertens Res 2006;29:645–653.
   PubMed Web of Science ®Google Scholar
• Protogerou AD, Safar ME, Iaria P, Safar H, Le Dudal K, Filipovsky J, Henry O, Ducimetere P, Blacher J. Diastolic blood pressure and mortality in the elderly with cardiovascular disease. Hypertension 2007;50:172–180.
   PubMed Web of Science ®Google Scholar
• James GD, Pickering TG, Yee LS, Harshfield GA, Riva S, Laragh JH. The reproducibility of average ambulatory, home, and clinic pressures. Hypertension 1988;11:545–549.
   PubMed Web of Science ®Google Scholar
• Ohkubo T, Asayama K, Kikuya M, Metoki H, Hoshi H, Hashimoto J, Totsune K, Satoh H, Imai Y; Ohasama Study. How many times should blood pressure be measured at home for better prediction of stroke risk? Ten-year follow-up results from the Ohasama study. J Hypertens 2004;22:1099–1104.
   PubMed Web of Science ®Google Scholar